Comparing Corbus Pharmaceuticals (CRBP) and Omeros (OMER)
Corbus Pharmaceuticals (NASDAQ: CRBP) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.
Insider and Institutional Ownership
27.8% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.9% of Omeros shares are owned by institutional investors. 11.9% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 12.1% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for Corbus Pharmaceuticals and Omeros, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Corbus Pharmaceuticals presently has a consensus price target of $25.00, indicating a potential upside of 249.65%. Omeros has a consensus price target of $36.17, indicating a potential upside of 84.90%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than Omeros.
Valuation and Earnings
This table compares Corbus Pharmaceuticals and Omeros’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Corbus Pharmaceuticals||$1.91 million||205.40||-$19.99 million||($0.62)||-11.53|
|Omeros||$41.62 million||22.56||-$66.74 million||($1.28)||-15.28|
Corbus Pharmaceuticals has higher earnings, but lower revenue than Omeros. Omeros is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Corbus Pharmaceuticals has a beta of 175.11, suggesting that its share price is 17,411% more volatile than the S&P 500. Comparatively, Omeros has a beta of 3.58, suggesting that its share price is 258% more volatile than the S&P 500.
This table compares Corbus Pharmaceuticals and Omeros’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Omeros beats Corbus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company’s product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.